(Q44513033)

3 December 2017

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States (English)

1 reference

3 December 2017

0 references

United States of America

0 references

author

Jaime Caro

3

1 reference

3 December 2017

Kristen Migliaccio-Walle

1

1 reference

3 December 2017

Denis Getsios

2

1 reference

3 December 2017

Khajak J Ishak

4

1 reference

3 December 2017

Judith A O'Brien

5

1 reference

3 December 2017

George Papadopoulos

6

1 reference

3 December 2017

AHEAD Study Group

7

1 reference

3 December 2017

1 June 2003

1 reference

3 December 2017

Clinical Therapeutics

1 reference

3 December 2017

25

1 reference

3 December 2017

6

1 reference

3 December 2017

1806-1825

1 reference

The epidemic of Alzheimer's disease. How can we manage the costs?

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

The economic burden of Alzheimer's disease care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

The cost of Alzheimer's disease. Will drug treatment ease the burden?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

The impact of symptom severity on the cost of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Cognitive function and the costs of Alzheimer disease. An exploratory study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

The net cost of Alzheimer disease and related dementia: a population-based study of Georgia Medicaid recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Medical services utilization and charge comparisons between elderly patients with and without Alzheimer's disease in a managed care organization.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Donepezil use in managed Medicare: effect on health care costs and utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Galantamine: a review of its use in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Galantamine: additional benefits to patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Predicting 10-year care requirements for older people with suspected Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Galantamine: therapeutic effects beyond cognition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980171-6

7 January 2021

10.1016/S0149-2918(03)80171-6

Identifiers

DOI

1 reference

3 December 2017

1 reference